Acorah Software Products - Accounts Production 15.0.500 false true false 4 November 2022 30 November 2023 30 November 2023 14461369 Tambi Mahmud Tambi Mahmud iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 14461369 2022-11-03 14461369 2023-11-30 14461369 2022-11-04 2023-11-30 14461369 frs-core:ShareCapital 2023-11-30 14461369 frs-core:RetainedEarningsAccumulatedLosses 2023-11-30 14461369 frs-bus:PrivateLimitedCompanyLtd 2022-11-04 2023-11-30 14461369 frs-bus:FilletedAccounts 2022-11-04 2023-11-30 14461369 frs-bus:SmallEntities 2022-11-04 2023-11-30 14461369 frs-bus:AuditExempt-NoAccountantsReport 2022-11-04 2023-11-30 14461369 frs-bus:SmallCompaniesRegimeForAccounts 2022-11-04 2023-11-30 14461369 frs-bus:Director1 2022-11-04 2023-11-30 14461369 frs-bus:CompanySecretary1 2022-11-04 2023-11-30 14461369 frs-countries:EnglandWales 2022-11-04 2023-11-30
Registered number: 14461369
Wellros Pharmaceuticals Ltd.
Unaudited Financial Statements
For the Period 4 November 2022 to 30 November 2023
Wizz Accounting Ltd
Contents
Page
Balance Sheet 1
Notes to the Financial Statements 2
Page 1
Balance Sheet
Registered number: 14461369
30 November 2023
Notes £ £
CURRENT ASSETS
Stocks 4 10,589
Cash at bank and in hand 2,345
12,934
Creditors: Amounts Falling Due Within One Year 5 (14,827 )
NET CURRENT ASSETS (LIABILITIES) (1,893 )
TOTAL ASSETS LESS CURRENT LIABILITIES (1,893 )
NET LIABILITIES (1,893 )
CAPITAL AND RESERVES
Called up share capital 6 1
Profit and Loss Account (1,894 )
SHAREHOLDERS' FUNDS (1,893)
For the period ending 30 November 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Tambi Mahmud
Director
2 August 2024
The notes on page 2 form part of these financial statements.
Page 1
Page 2
Notes to the Financial Statements
1. General Information
Wellros Pharmaceuticals Ltd. is a private company, limited by shares, incorporated in England & Wales, registered number 14461369 . The registered office is 128 City Road, London, EC1V 2NX.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
2.3. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
3. Average Number of Employees
Average number of employees, including directors, during the period was: NIL
-
4. Stocks
30 November 2023
£
Stock 10,589
5. Creditors: Amounts Falling Due Within One Year
30 November 2023
£
Other creditors 14,827
6. Share Capital
30 November 2023
£
Allotted, Called up and fully paid 1
Page 2